רווח תפעולי לפני פחת: biodesix.com (BDSX)

Expanded insurance coverage and integration into oncology centers are accelerating the growth of Biodesix, Inc. (BDSX). High physician confidence in AI-driven tests ensures the accuracy of non-invasive analysis. Monetization is based on B2B sales of diagnostic services to pulmonologists. This EBITDA_Co trend chart on GURU.Markets illustrates profit dynamics, where this metric equals 0.00, confirming the actual scale of the business.

This indicator captures actual cash flow from operating activities, excluding non-cash charges and tax adjustments to assess net production efficiency. Analyzing EBITDA allows for the tracking of revenue cyclicity, which for Biodesix, Inc. (BDSX) confirms steady cash flow growth driven by the broad clinical adoption of lung cancer molecular analysis systems.